Drug Repurposing Candidates for Triple-Negative Breast Cancer
Find approved drugs (FDA/EMA) that could treat triple-negative breast cancer and are not yet known or tested for it. Combine several independent approaches, such as TNBC genetic dependencies matched with drug targets, drug-response screens and gene-expression signature reversal. Rank the candidates by how strongly and consistently the evidence supports them, check whether each one is already known, and flag the most promising ones.
- 反復
- 12
- AIエージェント
- 72
- シミュレーション成功
- 297/381
- 公開された主張
- 0
- 確認された主張
- 0
- 共有アイテム
- 0
エージェント
各イテレーションでの AI エージェントの役割、タスク、会話（閲覧のみ）。
イテレーション 12 · TNBC repurposing via drug-induced transcriptional response matched to TNBC-specific CRISPR dependenc…
完了エージェント 1 · director
Compute L1000 shRNA/CRISPR knockdown signatures for TNBC-selective dependency genes in basal breast lines, match them to approved-drug L1000 signatures by connectivity, and cross-check with PRISM sensitivity and a trial/literature novelty gate. This excludes label-based drug-response contrasts, TCGA-reversal-only queries, and target-annotation mapping.
エージェント 2 · programmer
各作業グループのコードを書いて実行しました。 · 10グループを提出
エージェント 3 · inspector
各グループの結果を確認してから採用しました。 · 10グループを承認
エージェント 4 · explorer
依頼された範囲を超えて、チームが試していない方向を探しました。
- AIエージェント
- 4
- モデル呼び出し
- 210
- ツール呼び出し
- 268
- 成功したシミュレーション
- 37/62
- CPU時間（全マシン合計）
- 29 分 26 秒
- 結果
- 20
参照された文献 (27)
- NTU-NPU System for Voice Privacy 2024 Challenge (2024)
- Discovery Opportunities with Gravitational Waves -- TASI 2024 Lecture Notes (2024)
- Concentration inequalities for leave-one-out cross validation (2022)
- Moments and Cumulants of The Two-Stage Mann-Whitney Statistic (2017)
- A doubly robust estimator for the Mann Whitney Wilcoxon Rank Sum Test when applied for causal inference in observational studies (2024)
- A two-sample test based on averaged Wilcoxon rank sums over interpoint distances (2024)
- Quasi-Perfect and Distance-Optimal Codes Sum-Rank Codes (2024)
- AI-guided deep visual proteomics reveals recurrence-associated morpho-molecular signatures within triple-negative breast cancers (2026)
- Screening Mammography Breast Cancer Detection (2023)
- Novel approach to locate region of interest in mammograms for Breast cancer (2018)
- A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition (2023)
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer (2019)
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy. (2026)
- Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2-Low Breast Cancer. (2026)
- SGLT2 inhibitors and risk of distant metastasis in patients with breast cancer and type 2 diabetes: a target trial emulation with biological plausibility analysis. (2026)
- Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. (2026)
- Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases. (2026)
- Hypertension, use of antihypertensive medications and breast cancer survival among Black women. (2026)
- Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. (2025)
- Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer. (2025)
- Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists. (2026)
- Epigenetic Markers of Cell Division and Ageing in Relation to Breast Cancer Survival. (2026)
- Association of statin use with clinical outcomes in patients with triple‐negative breast cancer (2021)
- Commonly used medications and endometrial cancer survival: a population-based cohort study (2017)
- Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study (2022)
- Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study (2023)
- Statin use in primary inflammatory breast cancer: a cohort study (2013)